Company / Return on Equity (ROE)
Bristol Myers Squibb Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
38.2%
FY2025
5-year range
-54.8% / 38.2%
FY2021-FY2025
Trend
+169.7%
vs FY2024
Sector context
#9 of 190
Health Care
What the data says
Among 190 Health Care companies, Bristol Myers Squibb is in the top 5% for return on equity (roe). Return on Equity (ROE) has fluctuated over the past 10 years, ranging from -54.8% in FY2024 to 38.2% in FY2025.
Based on SEC 10-K filings.
38.2% in FY2025 with a 5-year CAGR of +62.0%. Top quartile in the Health Care sector.
Improved from 23.8% to 38.2% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +67.2pp
- 5-Year Change
- +62.0pp
- 10-Year Change
- -
Sector benchmark
+175.9% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 169.7% year-over-year.
- Currently 88.5pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2024.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 38.2% | +169.7% |
| FY2024 | -54.8% | -330.6% |
| FY2023 | 23.8% | +181.9% |
| FY2022 | -29.0% | -403.2% |
| FY2021 | 9.6% | +140.1% |
| FY2020 | -23.8% | -1322.6% |
| FY2019 | 1.9% | -93.9% |
| FY2018 | 31.8% | +270.3% |
| FY2017 | 8.6% | -30.8% |
| FY2016 | 12.4% | -31.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026